Aluminum phosphate

Manufactured by Brenntag

Sourced in United States, Denmark

Aluminum phosphate is a chemical compound used in various laboratory applications. It is a white, powdery substance with a chemical formula of AlPO4. Aluminum phosphate serves as a key ingredient in the formulation of various laboratory reagents and materials.

Automatically generated - may contain errors

Lab products found in correlation

Prevnar13, by Pfizer (3 mentions) Pneumovax, by Merck Group (3 mentions)

6 protocols using aluminum phosphate

Pneumococcal Polysaccharide-CRM197 Vaccine

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 7

Pneumococcal polysaccharide-CRM197 covalent. Compounds for serotypes containing 1, 3, 5, 7F, 14, 18C, 22F, 23F, 33F, 35B (10 serotypes polysaccharides) and cross-reactive polysaccharide compounds of (6A, 6B), (9V, 9N), (15A, 15B) and (19A, 19F) (8 serotypes) were combined to yield final polysaccharide concentration of 2.2-4.4 μg PS/mL (1.1-2.2 μg/human dose, 0.5 mL). Sodium chloride (150 mM) solution, 10-20 mM histidine, 20 mM HEPES or MOPS buffer and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant.

18-valent or higher valent (>20V-24V) covalent compound was aseptically filled in 2 mL sterile vials. PNEUMOVAX® (Merck, USA) and/or PREVNAR-13® (Pfizer, USA) were used as controls.

US10729763B2. Mixtures of polysaccharide-protein pegylated compounds (2020-08-04). Inventprise, LLC [US]. Inventors: Subhash V. Kapre [US], Anup K. Datta [US].

+ Open protocol

+ Expand

Quantifying rFLIPr IgG Antibody Titers

Check if the same lab product or an alternative is used in the 5 most similar protocols

C57BL/6 mice were preimmunized by subcutaneous injection without/with 30 µg rFLIPr plus 50 µL aluminum phosphate (Brenntag Biosector, Frederikssund, Denmark) on day -32 and -18. The blood samples were collected by submandibular blood collection on day -32 and -4, after which the blood was centrifuged, and the serum collected. The levels of rFLIPr IgG in the serum samples were determined by titrating the samples. The sera were diluted by 3-fold serial dilution at a 30-fold dilution of the serum samples. Briefly, purified rFLIPr was coated onto 96-well ELISA plates overnight. Bound IgG was detected with HRP-conjugated goat anti-mouse IgG. After the addition of TMB, the absorbance was measured with an ELISA reader at 450 nm. The ELISA end-point titers were defined as the serum dilution that produced an OD value of 0.2. The serum dilution was obtained from the titration curve by interpolation.

Wu C.C., Chiang C.Y., Liu S.J, & Chen H.W. (2021). A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment. Biomedicines, 9(7), 806.

+ Open protocol

+ Expand

Multivalent Pneumococcal Polysaccharide Conjugate

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 7

18-valent or higher valent (>20V-24V) covalent compound was aseptically filled in 2 mL sterile vials. PNEUMOVAX® (Merck, USA) and/or PREVNAR-13® (Pfizer, USA) were used as controls.

US11376323B2. Mixtures of polysaccharide protein pegylated compounds (2022-07-05). Inventprise, LLC [US]. Inventors: Subhash V. Kapre [US], Anup K. Datta [US].

+ Open protocol

+ Expand

Multivalent Pneumococcal Conjugate Vaccine

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 7

Pneumococcal Polysaccharide-CRM197 conjugates for serotypes containing 1, 3, 5, 7F, 14, 18C, 22F, 23F, 33F, 35B (10 serotypes Polysaccharides) and cross-reactive polysaccharide conjugates of (6A, 6B), (9V, 9N), (15A, 15B) and (19A, 19F) (8 serotypes) were combined to yield final polysaccharide concentration of 2.2-4.4 μg PS/mL (1.1-2.2 μg/human dose, 0.5 mL). Sodium chloride (150 mM) solution, 10-20 mM histidine, 20 mM HEPES or MOPS buffer and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant.

18-valent or higher valent (>20V-24V) conjugate was aseptically filled in 2 mL sterile vials. PNEUMOVAX® (Merck, USA) and/or PREVNAR-13® (Pfizer, USA) were used as controls.

US10688170B2. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity (2020-06-23). Inventprise, LLC [US]. Inventors: Subhash V. Kapre [US], Anup K. Datta [US].

+ Open protocol

+ Expand

RSV F Protein Nanoparticle Vaccine Production

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Briefly, the RSV F protein nanoparticle vaccine was manufactured by infecting Sf9 cells in exponential growth with baculovirus containing the RSV F gene, as previously described [25] (link). After infection, cells are collected by centrifugation, washed with sterile PBS, and then lysed in the presence of NP9 to release membrane bound RSV F protein. The supernatant containing the RSV F protein is clarified using depth filtration and then purified by ion exchange (trimethylaminoethyl, TMAE) chromatography. The flow-through fraction is affinity purified using lentil lectin washed and eluted from the column with buffer containing methyl-α-d-mannopyranoside (MMP) and polysorbate (PS) 80. The eluted fraction was further purified by cation exchange (sulfate) chromatography. The product was sterile filtered (0.22 μm) and formulated with buffer containing 25 mM sodium phosphate, pH 6.2, 1% histidine, 0.01% PS80. The vaccine was adsorbed to aluminum phosphate (aluminum as phosphate salt in 0.15 M NaCl without buffer) purchased from Brenntag Biosector, Frederikssund, Denmark.

Raghunandan R., Lu H., Zhou B., Xabier M.G., Massare M.J., Flyer D.C., Fries L.F., Smith G.E, & Glenn G.M. (2014). An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine, 32(48), 6485-6492.

+ Open protocol

+ Expand

Murine Immunization and Rabbit Antisera Generation

Check if the same lab product or an alternative is used in the 5 most similar protocols

All vaccines were prepared 1 day before immunization. Antigens were diluted to the appropriate concentration in saline, mixed with aluminum phosphate (Brenntag) (1.25-mg/mL final concentration of aluminum content), and then incubated at 4°C overnight with rotation (24 rpm). Mice received subcutaneous immunization with the indicated vaccine in 200 μL, up to three times, 2 weeks apart. Sera were collected 2 weeks after each immunization or as indicated for antibody analysis.
For rabbit immune serum generation, New Zealand White rabbits (n = 2 per group) received three intramuscular immunizations with CPS14-carrier 1 or CPS4-carrier 1 MAPS (1 μg of CPS content per dose), 2 weeks apart. Sera were collected 2 weeks after the last immunization and analyzed by an ELISA against CPS14 or CPS4. The serum that had the highest CPS-specific IgG antibody titer was used for an inhibition ELISA.

Zhang F., Thompson C., Ma N., Lu Y.J, & Malley R. (2022). Carrier Proteins Facilitate the Generation of Antipolysaccharide Immunity via Multiple Mechanisms. mBio, 13(3), e03790-21.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!